Episode

Rethinking hair loss treatment

Podcast
BioSpace
Published
Jun 3, 2026
Duration seconds
1305
Processing state
not_requested
Canonical source
https://api.riverside.com/hosting-analytics/media/73d4d606e42c9a64edf4618a9552f73113027cc79b3d80f88933008281a6417c/eyJlcGlzb2RlSWQiOiJmNWQ3YmM4ZC0xNmQ0LTRmODEtOTJhOS01YTFhNTczY2JkNmEiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyMDBiZDIxNGQ3Njg3ZjA1MDZhY2NmL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTNfXzEzLTExLTE0Lm1wMyJ9.mp3
Audio
https://api.riverside.com/hosting-analytics/media/73d4d606e42c9a64edf4618a9552f73113027cc79b3d80f88933008281a6417c/eyJlcGlzb2RlSWQiOiJmNWQ3YmM4ZC0xNmQ0LTRmODEtOTJhOS01YTFhNTczY2JkNmEiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyMDBiZDIxNGQ3Njg3ZjA1MDZhY2NmL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTNfXzEzLTExLTE0Lm1wMyJ9.mp3
JSON
/v1/public/podcasts/biospace-6696251/episodes/rethinking-hair-loss-treatment
Markdown
/podcast/biospace-6696251/rethinking-hair-loss-treatment.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/rethinking-hair-loss-treatment/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/biospace-6696251/rethinking-hair-loss-treatment.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Daniel Gil , CEO, Pelage Pharmaceuticals Francisco Ramírez-Valle , Senior Vice President, Immunology Discovery, Eli Lilly Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.